Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Cesca Therapeutics I (KOOL)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (BATS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ fieldTitles[key] ]] [[ value ]] [[ value ]]
[[ ctrl.chartTitle ]]
Full Chart

Fundamentals

See More
  • Market Capitalization, $K 30,294
  • Shares Outstanding, K 9,900
  • Annual Sales, $ 11,930 K
  • Annual Income, $ -18,590 K
  • 36-Month Beta -0.64
  • Price/Sales 2.59
  • Price/Cash Flow 0.00
  • Price/Book 0.92

Price Performance

See More
Period Period Low Period High Performance
1-Month
2.93 +4.44%
on 03/22/17
3.55 -13.80%
on 03/28/17
-0.02 (-0.65%)
since 03/21/17
3-Month
2.72 +12.50%
on 03/08/17
3.80 -19.47%
on 03/15/17
+0.30 (+10.87%)
since 01/20/17
52-Week
1.85 +65.41%
on 05/16/16
7.39 -58.59%
on 08/03/16
-0.22 (-6.71%)
since 04/21/16

Most Recent Stories

More News
CESCA Therapeutics to Present at the 2017 International Symposium of Translational Medicine in Stem Cell Myocardial Repair

Cesca Therapeutics Inc. (Nasdaq:KOOL), a market leader in automated cell processing and point-of-care, autologous cell-based therapies, today announced that Dr. Xiaochun (Chris) Xu, Chairman and Interim...

KOOL : 3.06 (-1.92%)
Cesca Therapeutics' Management Delivers Keynote Speech at the 2017 Shenzhen International Precision Medicine Summit

Cesca Therapeutics Inc. (Nasdaq:KOOL), a market leader in automated cell processing and point-of-care, autologous cell-based therapies, today announced that Dr. Xiaochun (Chris) Xu, Chairman and Interim...

KOOL : 3.06 (-1.92%)
Cesca Therapeutics Announces Senior Management Promotions

Cesca Therapeutics Inc. (Nasdaq:KOOL), a market leader in automated cell processing and point-of-care, autologous cell-based therapies, today announced the following senior management promotions, effective...

KOOL : 3.06 (-1.92%)
Cesca CLI Feasibility Study Published in Peer-Reviewed Journal

Cesca Therapeutics Inc. (NASDAQ:KOOL), a market leader in automated cell processing and point-of-care, autologous cell-based therapies, today announced the publication in a peer reviewed journal of data...

KOOL : 3.06 (-1.92%)
Blog Coverage Cesca Therapeutics Announces Encouraging Results from a Study of its Treatment of Chronic Non-healing Ulcers

Upcoming AWS Coverage on Medtronic Post-Earnings Results

KOOL : 3.06 (-1.92%)
MDT : 80.48 (-0.67%)
Cesca Therapeutics Strengthens Leadership Team and Board of Directors

Appoints Ms. Vivian Liu as Chief Operating Officer

KOOL : 3.06 (-1.92%)
Cesca Therapeutics to Announce Second Quarter Fiscal 2017 Results on February 13, 2017

Cesca Therapeutics Inc. (NASDAQ:KOOL), a market leader in automated cellular processing and point-of-care autologous cell-based therapies, announced today it will report financial results for the fiscal...

KOOL : 3.06 (-1.92%)
Cesca Therapeutics Appoints Dr. Joseph Thomis to Its Board of Directors

Cesca Therapeutics Inc. (NASDAQ:KOOL), a market leader in automated cellular processing and point-of-care autologous cell-based therapeutics, today announced that Dr. Joseph Thomis will join the Company's...

KOOL : 3.06 (-1.92%)
Cesca Announces FDA Approval of IDE Supplement for Phase III Clinical Trial

Cesca Therapeutics Inc. (NASDAQ:KOOL), a market leader in automated cellular processing and point-of-care autologous cell-based therapies, announced today that the Company received approval from the U.S....

KOOL : 3.06 (-1.92%)
Cesca Therapeutics to Present at the 9th Annual LD Micro Main Event

Cesca Therapeutics Inc. (NASDAQ:KOOL), a market leader in automated cellular processing and point-of-care autologous cell-based therapeutics, today announced that it is scheduled to present at the 9th...

KOOL : 3.06 (-1.92%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 16% Buy with a Weakest short term outlook on maintaining the current direction.

Longer term, the trend strength is Minimum. Long term indicators fully support a continuation of the trend.

See More

Business Summary

Cesca Therapeutics Inc. is engaged in the research, development, and commercialization of autologous cell-based therapeutics for use in regenerative medicine. It also develops and manufactures automated blood and bone marrow processing systems and companion disposable products that enable the separation,...

See More

Support & Resistance

2nd Resistance Point 3.13
1st Resistance Point 3.10
Last Price 3.06
1st Support Level 3.04
2nd Support Level 3.01

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.